Gan & Lee Pharmaceuticals. (603087.SS)
CNY 45.54
(0.35%)
CNY 45.54
(0.35%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.44 Million CNY | -34.58% |
| 2022 | 8.32 Million CNY | -31.55% |
| 2021 | 12.16 Million CNY | -24.55% |
| 2020 | 16.12 Million CNY | 2262.38% |
| 2019 | 682.57 Thousand CNY | 737.52% |
| 2018 | 81.5 Thousand CNY | -71.05% |
| 2017 | 281.5 Thousand CNY | -91.49% |
| 2016 | 3.3 Million CNY | -94.56% |
| 2015 | 60.81 Million CNY | 52262.5% |
| 2014 | 116.15 Thousand CNY | -55.57% |
| 2013 | 261.42 Thousand CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 3.9 Million CNY | 0.0% |
| 2024 Q3 | 3.67 Million CNY | 0.0% |
| 2024 Q2 | 3.78 Million CNY | 0.0% |
| 2023 FY | 5.44 Million CNY | -34.58% |
| 2023 Q1 | 8.06 Million CNY | -3.13% |
| 2023 Q3 | 8.18 Million CNY | -4.05% |
| 2023 Q4 | 5.44 Million CNY | -33.41% |
| 2023 Q2 | 8.52 Million CNY | 5.69% |
| 2022 Q3 | 13.42 Million CNY | 1.33% |
| 2022 Q1 | 13.04 Million CNY | 7.22% |
| 2022 FY | 8.32 Million CNY | -31.55% |
| 2022 Q4 | 8.32 Million CNY | -37.97% |
| 2022 Q2 | 13.24 Million CNY | 1.55% |
| 2021 Q1 | 14.88 Million CNY | 1488078200.0% |
| 2021 Q3 | 13.76 Million CNY | -5.4% |
| 2021 Q2 | 14.54 Million CNY | -2.25% |
| 2021 Q4 | 12.16 Million CNY | -11.59% |
| 2021 FY | 12.16 Million CNY | -24.55% |
| 2020 Q3 | 2.14 Million CNY | -6.12% |
| 2020 FY | 16.12 Million CNY | 2262.38% |
| 2020 Q1 | 2.23 Million CNY | 227.92% |
| 2020 Q4 | 1.00 CNY | -100.0% |
| 2020 Q2 | 2.28 Million CNY | 1.92% |
| 2019 FY | 682.57 Thousand CNY | 737.52% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 682.57 Thousand CNY | 0.0% |
| 2018 FY | 81.5 Thousand CNY | -71.05% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 FY | 281.5 Thousand CNY | -91.49% |
| 2017 Q4 | 281.5 Thousand CNY | 0.0% |
| 2017 Q2 | 1.47 Million CNY | 0.0% |
| 2016 FY | 3.3 Million CNY | -94.56% |
| 2015 FY | 60.81 Million CNY | 52262.5% |
| 2014 FY | 116.15 Thousand CNY | -55.57% |
| 2013 FY | 261.42 Thousand CNY | 0.0% |